Free Trial
NASDAQ:XCUR

Exicure 5/16/2024 Earnings Report

Exicure logo
$5.60 -0.01 (-0.09%)
Closing price 08/29/2025 03:58 PM Eastern
Extended Trading
$5.97 +0.36 (+6.51%)
As of 08/29/2025 06:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Exicure EPS Results

Actual EPS
-$0.61
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Exicure Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Exicure Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Exicure's next earnings date is estimated for Wednesday, November 12, 2025, based on past reporting schedules.

Conference Call Resources

Exicure Earnings Headlines

Retire Comfortably with These New Monthly Income ETFs?
Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns just aren’t enough anymore. But what if you could reach your Freedom Number—the monthly income that makes retirement secure—using far less money than you thought possible? That’s exactly what Kelly G. discovered. She calls it “life-changing,” saying the income just keeps growing and that early retirement suddenly looks real. This strategy was once reserved for the ultra-wealthy, but it’s now available to everyday investors.tc pixel
Stocks to Watch: Exicure, TTEC
See More Exicure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Exicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Exicure and other key companies, straight to your email.

About Exicure

Exicure (NASDAQ:XCUR), an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

View Exicure Profile

More Earnings Resources from MarketBeat